Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial

被引：0
|
作者：
Ashina, M. [1 ]
Tepper, S. J. [2 ]
Reuter, U. [3 ]
Blumenfeld, A. M. [4 ]
Hutchinson, S. [5 ]
Xia, J. [6 ]
Miceli, R. [6 ]
Severt, L. [6 ]
Finnegan, M. [6 ]
Trugman, J. M. [6 ]
机构：
[1] Univ Copenhagen, Danish Headache Ctr, Glostrup, Denmark
[2] Geisel Sch Med Dartmouth, Hanover, NH USA
[3] Charite, Berlin, Germany
[4] Headache Ctr Southern Calif, Carlsbad, CA USA
[5] Orange Cty Migraine & Headache Ctr, Irvine, CA USA
[6] AbbVie, Madison, NJ USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0301
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [31] Early Onset of Efficacy With Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
    Ailani, Jessica
    Reuter, Uwe
    Graboski, Corrie
    Klein, Brad C.
    Yu, Sung Y.
    Nagy, Krisztian
    Guo, Hua
    Trugman, Joel
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 32 - 33
  • [32] Aripiprazole once-monthly for long-term maintenance treatment of schizophrenia: a 52-week open-label study
    Peters-Strickland, T.
    Baker, R. A.
    McQuade, R.
    Jin, N.
    Eramo, A.
    Perry, P.
    Johnson, B.
    Duca, A.
    Sanchez, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S542 - S542
  • [33] Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan
    Matsumoto, Hideo
    Ishigooka, Jun
    Ono, Hiroaki
    Tadori, Yoshihiro
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2018, 72 (09) : 701 - 712
  • [34] Aripiprazole once-monthly for long-term maintenance treatment of schizophrenia: A 52-week open-label study
    Baker, R.
    Peters-Strickland, T.
    McQuade, R. D.
    Jin, N.
    Eramo, A.
    Perry, P. P.
    Johnson, B. R.
    Duca, A. R.
    Sanchez, R.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 64 - 64
  • [35] Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
    Joseph R. Calabrese
    Na Jin
    Brian Johnson
    Pedro Such
    Ross A. Baker
    Jessica Madera
    Peter Hertel
    Jocelyn Ottinger
    Joan Amatniek
    Hiroaki Kawasaki
    International Journal of Bipolar Disorders, 6
  • [36] Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
    Calabrese, Joseph R.
    Jin, Na
    Johnson, Brian
    Such, Pedro
    Baker, Ross A.
    Madera, Jessica
    Hertel, Peter
    Ottinger, Jocelyn
    Amatniek, Joan
    Kawasaki, Hiroaki
    INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS, 2018, 6
  • [37] Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study
    Yamasaki, K.
    Nakagawa, H.
    Kubo, Y.
    Ootaki, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (03) : 741 - 751
  • [38] Once-Daily Oral Trovafloxacin in the Treatment of Diabetic Foot InfectionsResults of an Open-Label, Noncomparative, Multicentre Trial
    R. Daniel
    Drugs, 1999, 58 : 291 - 292
  • [39] ONCE-DAILY VIBEGRON 75 MG IMPROVES QUALITY-OF-LIFE AND INCONTINENCE EFFICACY ENDPOINTS IN PATIENTS WITH OVERACTIVE BLADDER: DOUBLE-BLIND 52-WEEK RESULTS FROM AN EXTENSION STUDY OF THE EMPOWUR INTERNATIONAL PHASE 3 TRIAL
    Staskin, D.
    Frankel, J.
    Varano, S.
    Shortino, D.
    Jankowich, R.
    Mudd, Jr P.
    NEUROUROLOGY AND URODYNAMICS, 2020, 39 : S330 - S331
  • [40] AN OPEN-LABEL, 52-WEEK EXTENSION STUDY ASSESSING TOLERABILITY AND EFFICACY OF GABAPENTIN ENACARBIL IN SUBJECTS WITH PRIMARY RESTLESS LEGS SYNDROME
    Ellenbogen, A. L.
    Thein, S.
    Winslow, D. H.
    Becker, P. M.
    Tolson, J.
    Conklin, H.
    Lassauzet, M.
    Chen, D.
    SLEEP, 2010, 33 : A263 - A263
12345